Early Experience of Treprostinil Dry‐Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center

ABSTRACT A dry powder inhaler (DPI) formulation of treprostinil was FDA‐approved in March 2022 for patients with pulmonary arterial hypertension or pulmonary hypertension associated with ILD (PH‐ILD). In this letter we describe our real‐world single‐center experience using Treprostinil DPI in patien...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jordin L. Rice, Ann Randall, Darlene Kim, Vera Pillitteri, Tim Lahm, Zulma X. Yunt, Jeffrey J. Swigris, M. Patricia George
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-01-01
Edice:	Pulmonary Circulation
Témata:	drug tolerability PH‐ILD real‐world experience
On-line přístup:	https://doi.org/10.1002/pul2.70277
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!